ReviewAnnals of hematology2022

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.

Xavier Leleu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.